Official UK procurement notice
Tocilizumab Subcutaneous Injection (RoActemra®)
Authority: The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS") (NHS & healthcare)
What is being bought
Published requirement descriptionThe supply of Tocilizumab Subcutaneous Injections (RoActemra®) to NHS Scotland which used to treat licensed indications. This medicine is not being procured to treat Covid-19.
CPV: Pharmaceutical products
How this framework works
From the published notice- Bids received
- 1 bids received · 1 suppliers appointed
The lotProcurement structure
single lot · no lot value publishedLot #1Supply of Tocilizumab Subcutaneous Injections (RoActemra®) to NHS ScotlandAwarded
Supply of Tocilizumab Subcutaneous Injections (RoActemra®) to NHS Scotland. The Authority has awarded this framework as a single supplier framework per line.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Award procedure without prior publication of a call for competition
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- Not stated in the notice; call-off rights may be limited to the establishing authority
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 3 Feb 2021, 10:24 GMT
- Last source update
- 3 Feb 2021, 10:24 GMT
- Authority reference
NP90720 (k)- FTS notice number
2021/S 000-002127- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-028fa5Find a Tender
- Why no open competition
The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons
- Published justification
The patent for Tocilizumab (RoActemra®) has expired December 2020, there is no known competition that has entered the UK market place and there is none anticipated for the initial duration of the framework agreement.
- Review procedure
Economic operators should approach the contracting authority in the first instance. However, the only formal remedy is to apply to the courts:
An economic operator that suffers, or is at risk of suffering, loss or damage attributable to a breach of duty under the Public Contracts (Scotland) Regulations 2015 or the Procurement Reform (Scotland) Act 2014, may bring proceedings in the Sheriff Court or the Court of Session.
Publisher note: The total value in Sections II.1.7 and V.2.4 refers to the twenty four (24) months initial period with the option to extend by up to a total period of twenty four (24) months. (SC Ref:642715)
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast1 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.
Contracts
Contract 002127-2021-NP90720 (k)-1
- Signed
- 10 Dec 2020
- Value
- £25,050,684
- Status
- active
Bid statistics published by the authority
| Bids | SME | VCSE | Valid bid range |
|---|---|---|---|
| 1bids · 1 electronic · 1 from abroad | 0 | — | — |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- Edinburgh Sheriff CourtReview body
Framework contractors & participating bidders
1 commercial party on the notice- Roche Products LtdFramework contractor
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.